Financial reports
10-Q
2014 Q1
Quarterly report
9 May 14
10-K/A
2013 FY
Annual report (amended)
30 Apr 14
10-K
2013 FY
Annual report
11 Mar 14
10-Q
2013 Q3
Quarterly report
5 Nov 13
10-Q
2013 Q2
Quarterly report
6 Aug 13
10-Q
2013 Q1
Quarterly report
1 May 13
10-K/A
2012 FY
Annual report (amended)
14 Mar 13
10-K
2012 FY
Annual report
7 Mar 13
10-Q
2012 Q3
Quarterly report
7 Nov 12
10-Q
2012 Q2
Quarterly report
7 Aug 12
Current reports
8-K
Completion of Acquisition or Disposition of Assets
24 Jun 14
8-K
Other Events
12 May 14
8-K
Entry into a Material Definitive Agreement
8 May 14
8-K
Chelsea Therapeutics Announces FDA Accelerated Approval of NORTHERATM (Droxidopa)for the Treatment of Symptomatic NOH
19 Feb 14
8-K
Regulation FD Disclosure
14 Feb 14
8-K
Chelsea Therapeutics Names Keith W. Schmidt Chief Commercial Officer
30 Jan 14
8-K
Chelsea Therapeutics Announces Joseph G. Oliveto Named President and Chief Executive Officer, Director
27 Jan 14
8-K
Chelsea Therapeutics Announces Public Offering of Common Stock
15 Nov 13
8-K
Termination of a Material Definitive Agreement
5 Nov 13
8-K
Other Events
10 Oct 13
Registration and prospectus
15-12G
Securities registration termination
3 Jul 14
POS AM
Prospectus update (post-effective amendment)
25 Jun 14
POS AM
Prospectus update (post-effective amendment)
25 Jun 14
POS AM
Prospectus update (post-effective amendment)
25 Jun 14
POS AM
Prospectus update (post-effective amendment)
25 Jun 14
POS AM
Prospectus update (post-effective amendment)
25 Jun 14
POS AM
Prospectus update (post-effective amendment)
25 Jun 14
S-8 POS
Registration of securities for employees (post-effective amendment)
25 Jun 14
POS AM
Prospectus update (post-effective amendment)
25 Jun 14
POS AM
Prospectus update (post-effective amendment)
25 Jun 14
Proxies
DEF 14A
Definitive proxy
30 Apr 13
PRE 14A
Preliminary proxy
19 Apr 13
DEF 14A
Definitive proxy
30 Apr 12
DEF 14A
Definitive proxy
15 Apr 11
DEF 14A
Definitive proxy
26 Apr 10
PRE 14A
Preliminary proxy
1 Apr 10
DEF 14A
Definitive proxy
27 Apr 09
PRER14A
Preliminary revised proxy
8 Apr 09
PRE 14A
Preliminary proxy
1 Apr 09
DEF 14A
Definitive proxy
29 Apr 08
Other
EFFECT
Notice of effectiveness
26 Jun 14
EFFECT
Notice of effectiveness
26 Jun 14
EFFECT
Notice of effectiveness
26 Jun 14
EFFECT
Notice of effectiveness
26 Jun 14
EFFECT
Notice of effectiveness
26 Jun 14
EFFECT
Notice of effectiveness
26 Jun 14
EFFECT
Notice of effectiveness
26 Jun 14
EFFECT
Notice of effectiveness
26 Jun 14
EFFECT
Notice of effectiveness
26 Jun 14
UPLOAD
Letter from SEC
10 Jun 14
Ownership
SC 13G
Chelsea Therapeutics International, Ltd.
28 May 14
SC 13G
Chelsea Therapeutics International, Ltd.
14 Feb 14
SC 13G/A
Chelsea Therapeutics International, Ltd.
14 Feb 14
SC 13G/A
Chelsea Therapeutics International, Ltd.
3 Feb 14
SC 13G
Chelsea Therapeutics International, Ltd.
28 Jan 14
SC 13D/A
Chelsea Therapeutics International, Ltd.
21 Nov 13
SC 13D/A
Chelsea Therapeutics International, Ltd.
17 Jun 13
SC 13D/A
AUSTIN JOSIAH T
4 Mar 13
SC 13D/A
AUSTIN JOSIAH T
19 Dec 12
SC 13D/A
AUSTIN JOSIAH T
6 Jul 12